ArticleJournal of clinical laboratory analysis2020
Circular RNA VRK1 correlates with favourable prognosis, inhibits cell proliferation but promotes apoptosis in breast cancer.
Article in Journal of clinical laboratory analysis, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 4 syntheses or guidelines pooled it, 30 citations in OpenAlex.
- Influence of dysregulated expression of circular RNA on the diagnosis and prognosis of breast cancer in Asia: a meta-analysis study.BMJ open · 2021Pooled it
- CircRNAs as promising biomarker in diagnosis of breast cancer: An updated meta-analysis.Journal of clinical laboratory analysis · 2021Pooled it
- The Regulation Network and Clinical Significance of Circular RNAs in Breast Cancer.Frontiers in oncology · 2021Pooled it
- Circular RNA profiling facilitates the diagnosis and prognostic monitoring of breast cancer: A pair-wise meta-analysis.Journal of clinical laboratory analysis · 2021Pooled it
- The involvement of circular RNAs in breast cancer metastasis: Insight into EMT-related signaling pathways.BioImpacts : BI · 2026Review
- Decoding Breast Cancer: Emerging Molecular Biomarkers and Novel Therapeutic Targets for Precision Medicine.International journal of molecular sciences · 2025Review
- Role of circRNAs in regulating cell death in cancer: a comprehensive review.Cell biochemistry and biophysics · 2025Review
- CircRNAs and miRNAs: Key Player Duo in Breast Cancer Dynamics and Biomarkers for Breast Cancer Early Detection and Prevention.International journal of molecular sciences · 2024Review
- Inverse Impact of Cancer Drugs on Circular and Linear RNAs in Breast Cancer Cell Lines.Non-coding RNA · 2023Article
- Circ VRK1/microRNA-17/PTEN axis modulates the angiogenesis of human brain microvascular endothelial cells to affect injury induced by oxygen-glucose deprivation/reperfusion.BMC neuroscience · 2023Article
- Downregulation of VRK1 Inhibits Progression of Lung Squamous Cell Carcinoma through DNA Damage.Canadian respiratory journal · 2023Article
- Circular RNAs: biology and clinical significance of breast cancer.RNA biology · 2023Review
- Exosomal circular RNAs: New player in breast cancer progression and therapeutic targets.Frontiers in genetics · 2023Review
- circRNAs and their relationship with breast cancer: a review.World journal of surgical oncology · 2022Review
- Circular RNAs as Potential Biomarkers in Breast Cancer.Biomedicines · 2022Review
- Circular RNA circ_0000518 promotes breast cancer progression through the microRNA-1225-3p/SRY-box transcription factor 4 pathway.Bioengineered · 2022Article
- Serum Circ-FAF1/Circ-ELP3: A novel potential biomarker for breast cancer diagnosis.Journal of clinical laboratory analysis · 2021Article
- The Biogenesis and Functions of circRNAs and Their Roles in Breast Cancer.Frontiers in oncology · 2021Review
- Identification of plasma hsa_circ_0008673 expression as a potential biomarker and tumor regulator of breast cancer.Journal of clinical laboratory analysis · 2020Article
- CircAP2A2 acts as a ceRNA to participate in infantile hemangiomas progression by sponging miR-382-5p via regulating the expression of VEGFA.Journal of clinical laboratory analysis · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aimed to evaluate the correlation between the circular RNA VRK serine/threonine kinase 1 (circ-VRK1) and the clinicopathological features and survival outcomes of breast cancer patients and determine its effects on breast cancer cell proliferation and apoptosis.
methodsA total of 350 breast cancer tissues and 163 breast cancer adjacent tissues, as controls, were acquired from Specimen House. Circ-VRK1 expression was measured using qPCR. The correlations between circ-VRK1 expression and demographic characteristics, tumour features and overall survival were analysed. In vitro, the effects of circ-VRK1 on breast cancer cell proliferation and apoptosis were measured by upregulating and downregulating circ-VRK1 expression via plasmid transfection.
resultsCirc-VRK1 was downregulated in breast cancer tissues compared with adjacent tissues and represented a good value in distinguishing breast cancer tissues from the adjacent tissues. Circ-VRK1 was associated with smaller tumour size, reduced T stage and lower TNM stage, and circ-VRK1 was also an independent predictor of better overall survival. According to the in vitro experiments, circ-VRK1 expression was lower in breast cancer cell lines (including BT474, MDA-MB-453 and MDA-MB-231) than in a normal breast epithelial cell line (MCF10A), and circ-VRK1 inhibited cell proliferation but promoted cell apoptosis in MDA-MB-231 cells.
conclusionCirc-VRK1 is downregulated in tumour tissues and associated with reduced tumour stage as well as better survival, and it inhibits cell proliferation but promotes cell apoptosis in breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.